{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:23:34Z","timestamp":1779377014963,"version":"3.53.1"},"publisher-location":"New York, NY","reference-count":89,"publisher":"Springer US","isbn-type":[{"value":"9781071619230","type":"print"},{"value":"9781071619247","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1924-7_6","type":"book-chapter","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T22:02:37Z","timestamp":1646258557000},"page":"89-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peptides as Therapeutic Agents for Atherosclerosis"],"prefix":"10.1007","author":[{"given":"C. Roger","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayakonda","family":"Palgunachari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wolkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Anantharamaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/pr.58.3.1","volume":"58","author":"A Kontush","year":"2006","unstructured":"Kontush A, Chapman J (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 58:342\u2013374","journal-title":"Pharmacol Rev"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1001\/jama.1977.03280220037017","volume":"238","author":"SB Hulley","year":"1977","unstructured":"Hulley SB, Cohen R, Widdowson G (1977) Plasma high-density lipoprotein cholesterol level. Influence of risk factor intervention. JAMA 238:2269\u20132271","journal-title":"JAMA"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1172\/JCI114558","volume":"85","author":"JJ Badimon","year":"1990","unstructured":"Badimon JJ, Badimon L, Fuster V (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85:1234\u20131241","journal-title":"J Clin Invest"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/353265a0","volume":"353","author":"EM Rubin","year":"1991","unstructured":"Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353:265\u2013267","journal-title":"Nature"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"S Nissen","year":"2003","unstructured":"Nissen S, Tusnoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R (2003) Effect of apoA-I Milano on atherosclerosis in patients with acute coronary syndromes. A randomized controlled trail. JAMA 290:2292\u20132300","journal-title":"JAMA"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","volume":"100","author":"M Erickson","year":"1999","unstructured":"Erickson M, Carson LA, Miettinen TA, Angelin B (1999) Stimulation of fecal excretion after infusion of recombinant proapolipoproteinA-I. Circulation 100:594\u2013598","journal-title":"Circulation"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/01.ATV.19.4.979","volume":"19","author":"MN Nanjee","year":"1999","unstructured":"Nanjee MN, Doran JE, Lerch PG, Miller NE (1999) Acute effects of intravenous infusion of ApoA-I\/phosphatitylcholine discs on plasma lipoproteins in humans. Atheroscler Thromb Vasc Biol 19:979\u2013989","journal-title":"Atheroscler Thromb Vasc Biol"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1073\/pnas.89.15.6993","volume":"89","author":"ST Kunitake","year":"1992","unstructured":"Kunitake ST, Jarvis MR, Hamilton RL, Kane JP (1992) Binding of transition metals by apolipoprotein A-I\u2013containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A 89:6993\u20136997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4037\/ajcc2005.14.3.244","volume":"14","author":"LG Futterman","year":"2005","unstructured":"Futterman LG, Lemberg L (2005) Apo A-I Milano. Am J Crit Care 14:244\u2013247","journal-title":"Am J Crit Care"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa070635","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM (2007) Effect of Torcetrapib on the progression of coronary atherosclerosis. NEJM 356:1304\u20131316","journal-title":"NEJM"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/0021-9150(96)05851-0","volume":"124","author":"WP Castellini","year":"1996","unstructured":"Castellini WP (1996) Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124:S1\u2013S9","journal-title":"Atherosclerosis"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","volume":"95","author":"PJ Barter","year":"2004","unstructured":"Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res 95:764\u2013772","journal-title":"Circ Res"},{"key":"6_CR13","first-page":"173","volume":"37","author":"M Navab","year":"2005","unstructured":"Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Wagner AC, Shaposhnik Z, Fogelman AM (2005) The double jeopardy of HDL. Anals Med 37:173\u2013178","journal-title":"Anals Med"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA (2019) Apolipoprotein B containing particles and cardiovascular risk. JAMA Cardiol 4:1287\u20131295","journal-title":"JAMA Cardiol"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1161\/hc4401.098467","volume":"104","author":"PK Shah","year":"2001","unstructured":"Shah PK, Kaul S, Nilsson J, Cercek B (2001) Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104:2376\u20132383","journal-title":"Circulation"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bbalip.2011.08.003","volume":"182","author":"AJ Murphy","year":"2012","unstructured":"Murphy AJ, Westerterp M, Yvan-Charvel L, Tall AR (2012) Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta 182:513\u2013521","journal-title":"Biochim Biophys Acta"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0014-5793(74)80064-5","volume":"38","author":"JP Segrest","year":"1974","unstructured":"Segrest JP, Jackson RL, Morrisett JD, Gotto AM Jr (1974) A molecular theory of lipid-protein interactions in plasma lipoproteins. FEBS Lett 38:247\u2013253","journal-title":"FEBS Lett"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0065-3233(08)60643-9","volume":"45","author":"JP Segrest","year":"1994","unstructured":"Segrest JP, Brouillette CG, Garber DW, Harvey S, Anantharamaiah GM (1994) The amphipathic \u03b1-helix: a multifunctional and structural motif in plasma lipoproteins. Adv Protein Chem 45:303\u2013309","journal-title":"Adv Protein Chem"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"10248","DOI":"10.1016\/S0021-9258(17)39238-4","volume":"260","author":"GM Anantharamaiah","year":"1985","unstructured":"Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, Segrest JP (1985) Studies of synthetic peptide analogs of the amphiphatic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 260:10248\u201310255","journal-title":"J Biol Chem"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1529\/biophysj.104.047480","volume":"89","author":"C Arnulphi","year":"2005","unstructured":"Arnulphi C, Sanchez SA, Tricerri A, Gratton E, Jonas A (2005) Interaction of human apolipoprotein A-I with model membranes exhibiting lipid domains. Biophys J 89:285\u2013295","journal-title":"Biophys J"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1194\/jlr.M800075-JLR200","volume":"49","author":"BJ Van Lenten","year":"2008","unstructured":"Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49:2302\u20132311","journal-title":"J Lipid Res"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1172\/JCI115532","volume":"88","author":"M Navab","year":"1991","unstructured":"Navab M, Imes SS, Hama SY, Hough GP, Lori A, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Lakas H, Fogelman AM (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88:2039\u20132046","journal-title":"J Clin Invest"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0021-9150(94)05524-M","volume":"115","author":"MI Mackness","year":"1995","unstructured":"Mackness MI, Durrington PN (1995) HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115:243\u2013253","journal-title":"Atherosclerosis"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0022-2275(20)31163-9","volume":"42","author":"DW Garber","year":"2001","unstructured":"Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, Fogelman A, Segrest JP, Anantharamaiah GM (2001) A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 42:545\u2013552","journal-title":"J Lipid Res"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/01.RES.0000181229.69508.2f","volume":"97","author":"M Navab","year":"2005","unstructured":"Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Mishra VK, Palgunachari MN, Fogelman AM (2005) Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 97:524\u2013532","journal-title":"Circ Res"},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1161\/01.CIR.0000147232.75456.B3","volume":"110","author":"BJ Van Lenton","year":"2004","unstructured":"Van Lenton BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui K-W, Nayak DP, Fogelman AM (2004) D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110:3252\u20133258","journal-title":"Circulation"},{"issue":"5","key":"6_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064486","volume":"8","author":"OF Sharifov","year":"2013","unstructured":"Sharifov OF, Xu X, Gaggar A, Grizzle WE, Mishra VK, Honavar J, Litovsky SH, Palgunachari MN, White CR, Anantharamaiah GM, Gupta H (2013) Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis. PLoS One 8(5):e64486","journal-title":"PLoS One"},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/01.RES.0000176530.66400.48","volume":"97","author":"H Gupta","year":"2005","unstructured":"Gupta H, Dai L, Datta G, Garber DW, Grenett H, Lee Y, Mishra VK, Palgunachari MN, Handattu S, Gianturco SH, Bradley W, Anantharamaiah GM, White CR (2005) Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97:236\u2013243","journal-title":"Circ Res"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yjmcc.2017.01.017","volume":"105","author":"D Liu","year":"2017","unstructured":"Liu D, Ding Z, Wu M, Xu W, Qian M, Du Q, Zhang L, Cui Y, Zheng J, Chang H, Huang C, Lin D, Wang Y (2017) The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS\/HO-1 pathway. J Mol Cell Cardiol 105:77\u201388","journal-title":"J Mol Cell Cardiol"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1161\/CIRCULATIONAHA.104.517102","volume":"111","author":"AL Kruger","year":"2005","unstructured":"Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, Abraham NG (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111:3126\u20133134","journal-title":"Circulation"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1194\/jlr.M600214-JLR200","volume":"47","author":"GM Buga","year":"2006","unstructured":"Buga GM, Frank JS, Mottino GA, Hendizadeh M, Hakhamian A, Tillisch JH, Reddy ST, Navab M, Anantharamaiah GM, Ignarro LJ, Fogelman AM (2006) D-4F decreases brain arteriole inflammattion and improves cognitive performance in LDL receptor-null-mice on a Western diet. J Lipid Res 47:2148\u20132160","journal-title":"J Lipid Res"},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1161\/01.ATV.0000167412.98221.1a","volume":"25","author":"M Navab","year":"2005","unstructured":"Navab M, Anantharamaiah GM, Hama S, Hogh G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman A (2005) D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25:1426\u20131432","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1161\/01.CIR.0000061949.17174.B6","volume":"107","author":"Z Ou","year":"2003","unstructured":"Ou Z, Ou J, Ackerman A, Oldham KT, Prichard KA Jr (2003) L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 107:1520\u20131524","journal-title":"Circulation"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.nbd.2009.03.007","volume":"34","author":"SP Handattu","year":"2009","unstructured":"Handattu SP, Garber DW, Monroe CE, van Groen T, Kadish I, Nayyar G, Cao D, Palgunachari MN, Li L, Anantharamaiah GM (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer\u2019s Disease. Neurobiol Dis 34:525\u2013534","journal-title":"Neurobiol Dis"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1016\/j.transproceed.2006.10.156","volume":"38","author":"GT Schnickel","year":"2006","unstructured":"Schnickel GT, Hsieh GR, Kachikwu EL, Garcia C, Shefizadeh A, Fishbein M, Ardehali A (2006) Cytoprotective gene HO-1 and chronic rejection in heart transplantation. Transplant Proc 38:3259\u20133262","journal-title":"Transplant Proc"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1194\/jlr.M012724","volume":"252","author":"SD Nandedkar","year":"2011","unstructured":"Nandedkar SD, Weihrauch D, Xu H, Shi Y, Feroah T, Hutchins W, Rickaby DA, Duzgunes N, Hillery CA, Konduri KS, Pritchard KA Jr (2011) D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res 252:499\u2013508","journal-title":"J Lipid Res"},{"issue":"2","key":"6_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.clim.2008.01.016","volume":"127","author":"C Charles-Schoeman","year":"2008","unstructured":"Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E (2008) Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 127(2):234\u2013244","journal-title":"Clin Immunol"},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"628147","DOI":"10.1155\/2012\/628147","volume":"2012","author":"J Cao","year":"2012","unstructured":"Cao J, Puri N, Sodhi K, Bellner L, Abraham NG, Kappas A (2012) ApoA-I mimetic rescues the diabetic phenotype of HO-2 knockout mice via an increase in HO-1 adiponectin and LKBI signaling pathway. Int J Hypertens 2012:628147","journal-title":"Int J Hypertens"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1194\/jlr.M800610-JLR200","volume":"50","author":"SJ Peterson","year":"2009","unstructured":"Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L\u2019Abbate A, Abraham NG (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 50:1293\u20131304","journal-title":"J Lipid Res"},{"key":"6_CR40","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1002\/jcb.23188","volume":"112","author":"C Vecoli","year":"2011","unstructured":"Vecoli C, Cao J, Neglia D, Inoue K, Sodhi K, Vanella L, Gabrielson KK, Bedia D, Paolocci N, L\u2019abbate A, Abraham NG (2011) Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice. J Cell Biochem 112:2616\u20132626","journal-title":"J Cell Biochem"},{"key":"6_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.4","volume":"12","author":"JS Marino","year":"2012","unstructured":"Marino JS, Peterson SJ, Li M, Vanella L, Sodhi K, Hill JW, Abraham NG (2012) ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice. Nutr Diab 12:e33","journal-title":"Nutr Diab"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4161\/cc.11.4.19125","volume":"11","author":"L Vanella","year":"2012","unstructured":"Vanella L, Li M, Kim D, Malfa G, Bellner L, Kawakami T, Abraham NG (2012) ApoA1: mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in hemoxygenase (HO-1) and Wnt10b. Cell Cycle 11:706\u2013714","journal-title":"Cell Cycle"},{"key":"6_CR43","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1194\/jlr.M008086","volume":"51","author":"L Dai","year":"2010","unstructured":"Dai L, Datta G, Zhang Z, Gupta H, Patel R, Honavar J, Modi S, Wyss JM, Palgunachari M, Anantharamaiah GM, White CR (2010) The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 51:2695\u20132705","journal-title":"J Lipid Res"},{"key":"6_CR44","first-page":"2337","volume":"107","author":"Z Ou","year":"2003","unstructured":"Ou Z, Jones DW, Holzhauer S, Hartoum OA, Ackerman AW, Gutternan DD, Guice K, Oldham KT, Hillery CA, Prichard KA Jr (2003) L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle. Cell Dis 107:2337\u20132341","journal-title":"Cell Dis"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"19997","DOI":"10.1073\/pnas.1009010107","volume":"107","author":"F Su","year":"2010","unstructured":"Su F, Kozaka KR, Imaizumib S, Gao F, Amneusa MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Mohamad M, Fogelman AM, Reddy ST, Farias-Eisner R (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 107:19997\u201312000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"6_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1161\/ATVBAHA.109.200162","volume":"30","author":"GM Buga","year":"2010","unstructured":"Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, Chanslor S, Anantharamaiah GM, Fogelman AM (2010) 4F ameliorates hyperlipidemia-induced platelet aggregation inhibition L-4F alters hyperlipidemic (but not normal) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol 30(2):283\u2013292","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6_CR47","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1172\/JCI123700","volume":"129","author":"D Meriwether","year":"2019","unstructured":"Meriwether D, Sulaiman D, Volpe C, Dorfman A, Grijalva V, Dorreh N, Solorzano-Vargas RS, Wang J, O\u2019Connor E, Papesh J, Larauche M, Trost H, Palgunachari MN, Anantharamaiah GM, Herschman HR, Martin MG, Fogelman AM, Reddy ST (2019) Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J Clin Invest 129:3670\u20133685","journal-title":"J Clin Invest"},{"key":"6_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1167\/iovs.18-25786","volume":"60","author":"M Rudolf","year":"2019","unstructured":"Rudolf M, Curcio C, Schl\u00f6tzer-Schrehardt U, Mir A, Sefat M, Tura A, Aherrahrou Z, Brinkmann M, Grisanti S, Miura Y, Ranjbar M (2019) Apolipoprotein A-I mimetic peptide L-4F removes Bruch\u2019s membrane lipids in aged nonhuman primates. Invest Ophthalmol Vis Sci 60:461\u2013472","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/02713683.2017.1370118","volume":"43","author":"M Rudolf","year":"2018","unstructured":"Rudolf M, Mir Mohi Sefat A, Miura Y, Tura A, Raasch W, Ranjbar M, Grisanti S, Aherrahrou Z, Wagner A, Messinger JD, Garber DW, Anantharamaiah GM, Curcio CA (2018) ApoA-I mimetic peptide 4F reduces age-related lipid deposition in murine Bruch\u2019s membrane and causes its structural remodeling. Curr Eye Res 43:135\u2013146","journal-title":"Curr Eye Res"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"173051","DOI":"10.1016\/j.ejphar.2020.173051","volume":"876","author":"J Zhang","year":"2020","unstructured":"Zhang J, Cui Y, Li X, Xiao Y, Liu L, Jia F, He J, Xie X, Parthasarathy S, Hao H, Fang N (2020) 5F peptide promotes endothelial differentiation of bone marrow stem cells through activation of ERK1\/2 signaling. Eur J Pharmacol 876:173051\u2013173060","journal-title":"Eur J Pharmacol"},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.3390\/ijms21103519","volume":"21","author":"T Hamid","year":"2020","unstructured":"Hamid T, Ismahil MA, Bansal SS, Patel B, Goel M, White CR, Anantharamaiah GM, Prabhu SD (2020) The apolipoprotein A-I mimetic L-4F attenuates monocyte activation and adverse cardiac remodeling after myocardial infarction. Int J Mol Sci 21:3519\u20133534","journal-title":"Int J Mol Sci"},{"key":"6_CR52","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1194\/jlr.M800539-JLR200","volume":"50","author":"M Navab","year":"2009","unstructured":"Navab M, Ruchala P, Waring AJ, Lehrer RL, Hama S, Hough G, Palgunachari MN, Anantharamaiah GM, Fogelman AM (2009) A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res 50:1538\u20131547","journal-title":"J Lipid Res"},{"key":"6_CR53","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","volume":"109","author":"M Navab","year":"2004","unstructured":"Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM (2004) Oral D-4F causes formation of pre-\u03b2 high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215\u20133220","journal-title":"Circulation"},{"key":"6_CR54","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1016\/j.jmb.2018.08.018","volume":"430","author":"BR Sahoo","year":"2018","unstructured":"Sahoo BR, Genjo T, Cox SJ, Stoddard AK, Anantharamaiah GM, Fierke C, Ramamoorthy AJ (2018) Nanodisc-forming scaffold protein promoted retardation of amyloid-beta aggregation. Mol Biol 430:4230\u20134244","journal-title":"Mol Biol"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1194\/jlr.M800046-JLR200","volume":"49","author":"SJ Peterson","year":"2008","unstructured":"Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG (2008) L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 49:1658\u20131669","journal-title":"J Lipid Res"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1194\/jlr.M033555","volume":"54","author":"A Chattopadhyay","year":"2013","unstructured":"Chattopadhyay A, Navab M, Hough G, Gao F, Merriweather D, Grijalva V, Springstead JR, Palgnachari MN, Namiri-Kalantari R, Su F, Van Lenten BJ, Wagner AC, Anantharamaiah GM, Frais-Eisner R, Reddy ST, Fogelman AM (2013) A novel approach to apoA-I mimetic therapy. J Lipid Res 54:995\u20131010","journal-title":"J Lipid Res"},{"key":"6_CR57","doi-asserted-by":"publisher","first-page":"C1538","DOI":"10.1152\/ajpcell.00467.2009","volume":"298","author":"LE Smythies","year":"2010","unstructured":"Smythies LE, White CR, Maheshwari A, Palgunachari MN, Anantharamaiah GM, Chaddha M, Kurundkar AR, Datta G (2010) Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Phys Cell Physiol 298:C1538\u2013C1548","journal-title":"Am J Phys Cell Physiol"},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/01.CIR.0000142857.79401.69","volume":"110","author":"X Li","year":"2004","unstructured":"Li X, Chyu K-Y, Faria JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK (2004) Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110:1701\u20131705","journal-title":"Circulation"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1194\/jlr.M200475-JLR200","volume":"44","author":"AT Remaley","year":"2003","unstructured":"Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S, Brewer B (2003) Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 44:828\u2013836","journal-title":"J Lipid Res"},{"key":"6_CR60","doi-asserted-by":"publisher","first-page":"32273","DOI":"10.1074\/jbc.M804461200","volume":"283","author":"AA Sethi","year":"2008","unstructured":"Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D\u2019Souza W, Sviridov D, Remaley A (2008) Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 283:32273\u201332282","journal-title":"J Biol Chem"},{"key":"6_CR61","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1172\/JCI117515","volume":"94","author":"A Mendez","year":"1994","unstructured":"Mendez A, Anantharamaiah GM, Segrest JP, Oram JF (1994) Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 94:1698\u20131705","journal-title":"J Clin Invest"},{"key":"6_CR62","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1002\/anie.201713167","volume":"57","author":"C Barnaba","year":"2018","unstructured":"Barnaba C, Sahoo BR, Ravula T, Medina-Meza IG, Im SC, Anantharamaiah GM, Waskell L, Ramamoorthy A (2018) Cytochrome-P450-induced ordering of microsomal membranes modulates affinity for drugs. Angew Chem Int Ed Eng 57:3391\u20133395","journal-title":"Angew Chem Int Ed Eng"},{"key":"6_CR63","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1096\/fj.10-165670","volume":"25","author":"GD Wool","year":"2011","unstructured":"Wool GD, Cabana VG, Lukens J, Shaw PX, Binder CJ, Witztum JL, Reardon CA, Getz GS (2011) 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J 25:290\u2013300","journal-title":"FASEB J"},{"key":"6_CR64","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1194\/jlr.M003665","volume":"51","author":"JK Bielicki","year":"2010","unstructured":"Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51:1496\u20131503","journal-title":"J Lipid Res"},{"key":"6_CR65","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1021\/ja00507a068","volume":"101","author":"D Fukushima","year":"1979","unstructured":"Fukushima D, Kupferberg JP, Yokoyama S, Kroon DJ, Kaiser ET, K\u00e9zdy FJ (1979) A synthetic amphiphilic helical docosapeptide with the surface properties of plasma apolipoprotein A-I. J Am Chem Soc 101:3703\u20133704","journal-title":"J Am Chem Soc"},{"key":"6_CR66","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1016\/S0021-9258(20)79708-5","volume":"255","author":"S Yokohama","year":"1980","unstructured":"Yokohama S, Fukushima D, Kupferberg JP, K\u00e9zdy FJ, Kaiser ET (1980) The mechanism of activation of lecithin: cholesterol acyl transferase by apolipoprotein A-I and an amphiphilic peptide. J Biol Chem 255:7333\u20137339","journal-title":"J Biol Chem"},{"key":"6_CR67","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.ATV.17.3.580","volume":"17","author":"C Labuer","year":"1997","unstructured":"Labuer C, Lins L, Vanloo B, Brasseur R, Rossenue M (1997) Design of a new class of amphipathic helical peptides for the plasma apolipoproteins that promote cellular cholesterol efflux but do not activate LCAT. Arterioscler Thromb Vasc Biol 17:580\u2013588","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6_CR68","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1194\/jlr.M013144","volume":"52","author":"M Navab","year":"2011","unstructured":"Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hogh G, Hama S, Fogelman A (2011) Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 52:1200\u20131210","journal-title":"J Lipid Res"},{"key":"6_CR69","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1161\/01.ATV.12.8.886","volume":"12","author":"DW Garber","year":"1992","unstructured":"Garber DW, Venkatachalapathi YV, Gupta KB, Ibdah J, Phillips MC, Hazelrig A, Segrest J, Anantharamaiah GM (1992) Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Aterio Thromb 12:886\u2013894","journal-title":"Aterio Thromb"},{"key":"6_CR70","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","volume":"49","author":"LT Bloedon","year":"2008","unstructured":"Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49:1344\u20131352","journal-title":"J Lipid Res"},{"issue":"Suppl A","key":"6_CR71","first-page":"1014","volume":"49","author":"RL Dunbar","year":"2007","unstructured":"Dunbar RL, Bloedon LT, Duffy D, Norris RB, Movva, Navab M, Fogelman AM, Rader DJ (2007) Daily oral administration of the apolipoprotein A-I mimetic peptide D-4F in patients with coronary heart disease or equivalent risk improves high-density lipoprotein anti-inflammatory function. J Am Coll Cardiol 49(Suppl A):1014\u20131123","journal-title":"J Am Coll Cardiol"},{"key":"6_CR72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1194\/jlr.M011098","volume":"52","author":"CE Watson","year":"2011","unstructured":"Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, Navab M, Hama S, Hough G, Reddy ST, Soffer D, Rader DJ, Fogelman AM, Schecter A (2011) Treatment of patients with cardiovascular disease with L-4F, an apoA1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 52:361\u2013373","journal-title":"J Lipid Res"},{"key":"6_CR73","first-page":"275","volume":"8","author":"JD Harris","year":"2006","unstructured":"Harris JD, Evans V, Owen JS (2006) ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opion Mol Ther 8:275\u2013287","journal-title":"Curr Opion Mol Ther"},{"key":"6_CR74","doi-asserted-by":"publisher","first-page":"11142","DOI":"10.1021\/bi00035a020","volume":"34","author":"MA Clay","year":"1995","unstructured":"Clay MA, Anantharamaiah GM, Mistry MJ, Balasubramaniam A, Harmony JAK (1995) Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry 34:11142\u201311151","journal-title":"Biochemistry"},{"key":"6_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1172\/JCI1099","volume":"101","author":"IR Nikoulin","year":"1998","unstructured":"Nikoulin IR, Curtiss LK (1998) An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J Clin Invest 101:223\u2013234","journal-title":"J Clin Invest"},{"key":"6_CR76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1021\/bi991209w","volume":"39","author":"G Datta","year":"2000","unstructured":"Datta G, Chaddha M, Garber DW, Chung BH, Tytler EM, Dashti N, Bradley WA, Gianturco SH, Anantharamaiah GM (2000) The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 39:213\u2013220","journal-title":"Biochemistry"},{"key":"6_CR77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0021-9150(03)00101-1","volume":"168","author":"DW Garber","year":"2003","unstructured":"Garber DW, Handattu S, Aslan I, Datta G, Chaddha M, Anantharamaiah GM (2003) Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 168:229\u2013237","journal-title":"Atherosclerosis"},{"key":"6_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-60761-350-3_1","volume":"660","author":"G Datta","year":"2010","unstructured":"Datta G, Chaddha M, Handattu SP, Palgunachari MN, Nayyar G, Garber DW, Gupta H, White CR, Anantharamaiah GM (2010) ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity. Adv Exp Med Biol 660:1\u20134","journal-title":"Adv Exp Med Biol"},{"key":"6_CR79","doi-asserted-by":"crossref","unstructured":"Handattu SP, Monroe CE, Nayyar G, Palgunachari MN, Kadish I, van Groen T, Anantharamaiah GM, Garber DW (2013) In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-beta pathology. J Alzheimers Dis 36:335\u2013347","DOI":"10.3233\/JAD-122377"},{"key":"6_CR80","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1194\/jlr.M085985","volume":"59","author":"GM Anantharamaiah","year":"2018","unstructured":"Anantharamaiah GM, Garber DW, Goldberg D, Morell E, Datta G, Palgunachari MN, Registrar TC, Appt SE, White CR (2018) Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques. J Lipid Res 59:2075\u20132083","journal-title":"J Lipid Res"},{"key":"6_CR81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-3-319-17350-4_10","volume-title":"Apolipoprotein mimetics in the management of human disease","author":"DW Garber","year":"2015","unstructured":"Garber DW, Goldberg D, Anantharamaiah GM (2015) Apolipoprotein mimetic peptides: cholesterol-dependent and cholesterol-independent properties. In: Anantharamaiah GM, Goldberg D (eds) Apolipoprotein mimetics in the management of human disease. ADIS, Basel, pp 135\u2013156"},{"key":"6_CR82","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1194\/jlr.M006916","volume":"51","author":"SP Handattu","year":"2010","unstructured":"Handattu SP, Datta G, Epand RM, Epand RF, Palgunachari MN, Mishra VK, Monroe CE, Keenum TD, Chaddha M, Anantharamaiah GM, Garber DW (2010) Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J Lipid Res 51:3491\u20133499","journal-title":"J Lipid Res"},{"key":"6_CR83","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2010.09.030","volume":"213","author":"G Nayyar","year":"2010","unstructured":"Nayyar G, Handattu SP, Monroe CE, Chaddha M, Datta G, Mishra VK, Keenum TD, Palgunachari MN, Garber DW, Anantharamaiah GM (2010) Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects. Atherosclerosis 213:449\u2013457","journal-title":"Atherosclerosis"},{"key":"6_CR84","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1161\/CIRCULATIONAHA.104.497107","volume":"111","author":"H Gupta","year":"2005","unstructured":"Gupta H, White CR, Handattu S, Garber DW, Datta G, Chaddha M, Dai L, Gianturco SH, Bradley WA, Anantharamaiah GM (2005) Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circulation 111:3112\u20133118","journal-title":"Circulation"},{"key":"6_CR85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2012.10.064","volume":"227","author":"SP Handattu","year":"2013","unstructured":"Handattu SP, Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, Mishra VK, Datta G, Anantharamaiah GM (2013) Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 227:58\u201364","journal-title":"Atherosclerosis"},{"key":"6_CR86","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbrc.2013.06.020","volume":"436","author":"OF Sharifov","year":"2013","unstructured":"Sharifov OF, Nayyar G, Ternovoy VV, Mishra VK, Litovsky SH, Palgunachari MN, Garber DW, Anantharamaiah GM, Gupta H (2013) Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats. Biochem Biophys Res Commun 436:705\u2013710","journal-title":"Biochem Biophys Res Commun"},{"key":"6_CR87","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000334914","volume":"10","author":"MP Vitek","year":"2012","unstructured":"Vitek MP, Christensen DJ, Wilcock J, Davis WE, Van Nostrand Li FQ, Colton CA (2012) APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer\u2019s disease transgenics. Neurodegener Dis 10:122\u2013126","journal-title":"Neurodegener Dis"},{"key":"6_CR88","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-3-319-17350-4_11","volume-title":"Apolipoprotein mimetics in the management of human disease","author":"MP Vitek","year":"2015","unstructured":"Vitek MP, Li F, Colton CA (2015) Apolipoprotein-E and mimetics as targets and therapeutics for Alzheimer\u2019s Disease. In: Anantharamaiah GM, Goldberg D (eds) Apolipoprotein mimetics in the management of human disease. Springer International Publishing, Basel, pp 157\u2013182"},{"key":"6_CR89","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.transci.2018.01.002","volume":"57","author":"T Lappeg\u00e5rd","year":"2018","unstructured":"Lappeg\u00e5rd T, Abendstein Kjellmo C, Ljunggren S, Cederbrant K, Marcusson-St\u00e5hl M, Mathisen M, Karlsson H, Hovland A (2018) Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study. Transfus Apher Sci 57:91\u201396","journal-title":"Transfus Apher Sci"}],"container-title":["Methods in Molecular Biology","Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1924-7_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T09:06:50Z","timestamp":1666516010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1924-7_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071619230","9781071619247"],"references-count":89,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1924-7_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"2 March 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}